Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation

Veterinary Immunology and Immunopathology

Volumn 132, Issue 2-4, 2009, Pages 243-250

  Hadzijusufovic, Emir ^a,b   Peter, Barbara ^a,b   Rebuzzi, Laura ^a,b   Baumgartner, Christian ^b   Gleixner, Karoline V ^b   Gruze, Alexander ^c   Thaiwong, Tuddow ^d   Pickl, Winfried F ^c   Yuzbasiyan Gurkan, Vilma ^d   Willmann, Michael ^a   Valent, Peter ^b,e  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

c Kit mutation; Feline; Mast cell; Mastocytosis; Tyrosine kinase inhibitor

Indexed keywords

AMINO ACID; DASATINIB; HISTIDINE; IMATINIB; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; THREONINE; THYMIDINE; TRITIUM;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CAT; CELL ISOLATION; CONTROLLED STUDY; EXON; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HISTOPATHOLOGY; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MAST CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; SYSTEMIC MASTOCYTOSIS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CAT DISEASES; CATS; CELL PROLIFERATION; DNA PRIMERS; EXONS; FEMALE; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; STAUROSPORINE; TANDEM REPEAT SEQUENCES; THIAZOLES;

FELIDAE;

EID: 70449529779     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.05.007     Document Type: Article

References (43)

1. Agis H., Krauth M.T., Bohm A., Mosberger I., Mullauer L., Simonitsch-Klupp I., Walls A.F., Horny H.P., and Valent P. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am. J. Clin. Pathol. 125 (2006) 273-281
2. Akin C., Brockow K., D'Ambrosio C., Kirshenbaum A.S., Ma Y., Longley B.J., and Metcalfe D.D. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol. 31 (2003) 686-692
3. Akin C., and Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. J. Allergy Clin. Immunol. 114 (2004) 13-19
4. Allan R., Halsey T.R., and Thompson K.G. Splenic mast cell tumour and mastocytaemia in a cat: case study and literature review. N. Z. Vet. J. 48 (2000) 117-121
5. Carpenter J., Andrews L., and Holzworth J. Tumours and tumour-like lesions. In: Holzworth J. (Ed). Diseases of the Cat vol. 1 (1987), WB Saunders, Philadelphia, USA 406-596
6. Confer A.W., Langloss J.M., and Cashell I.G. Long-term survival of two cats with mastocytosis. J. Am. Vet. Med. Assoc. 172 (1978) 160-161
7. Dank G., Chien M.B., and London C.A. Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats. Am. J. Vet. Res. 63 (2002) 1129-1133
8. Downing S., Chien M.B., Kass P.H., Moore P.E., and London C.A. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am. J. Vet. Res. 63 (2002) 1718-1723
9. Droogendijk H.J., Kluin-Nelemans H.J., van Doormaal J.J., Oranje A.P., van de Loosdrecht A.A., and van Daele P.L. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107 (2006) 345-351
10. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y., Matsuzawa Y., Kitamura Y., and Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92 (1993) 1736-1744
11. Galli S.J., Tsai M., and Wershil B.K. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am. J. Pathol. 142 (1993) 965-974
12. Gleixner K.V., Mayerhofer M., Aichberger K.J., Derdak S., Sonneck K., Böhm A., Gruze A., Samorapoompichit P., Manley P.W., Fabbro D., Pickl W.F., Sillaber C., and Valent P. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 (2006) 752-759
13. Gleixner K.V., Mayerhofer M., Sonneck K., Gruze A., Samorapoompichit P., Baumgartner C., Lee F.Y., Aichberger K.J., Manley P.W., Fabbro D., Pickl W.F., Sillaber C., and Valent P. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92 (2007) 1451-1459
14. Gleixner K.V., Rebuzzi L., Mayerhofer M., Gruze A., Hadzijusufovic E., Sonneck K., Vales A., Kneidinger M., Samorapoompichit P., Thaiwong T., Pickl W.F., Yuzbasiyan-Gurkan V., Sillaber C., Willmann M., and Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp. Hematol. 35 (2007) 1510-1521
15. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol. Allergy Clin. North. Am. 26 (2006) 575-592
16. Gotlib J., Berubé C., Growney J.D., Chen C.C., George T.I., Williams C., Kajiguchi T., Ruan J., Lilleberg S.L., Durocher J.A., Lichy J.H., Wang Y., Cohen P.S., Arber D.A., Heinrich M.C., Neckers L., Galli S.J., Gilliland D.G., and Coutré S.E. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816 V KIT mutation. Blood 106 (2005) 2865-2870
17. Guerre R., Millet P., and Groulade P. Systemic mastocytosis in a cat: remission after splenectomy. J. Small Anim. Pract. 20 (1979) 769-772
18. Hantschel O., Rix U., Schmidt U., Bürckstümmer T., Kneidinger M., Schütze G., Colinge J., Bennett K.L., Ellmeier W., Valent P., and Superti-Furga G. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 13283-13288
19. Hoffmann K.M., Moser A., Lohse P., Winkler A., Binder B., Sovinz P., Lackner H., Schwinger W., Benesch M., and Urban C. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood 112 (2008) 1655-1657
20. Isotani M., Tamura K., Yagihara H., Hikosaka M., Ono K., Washizu T., and Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet. Immunol. Immunopathol. 114 (2006) 168-172
21. Jensen B.M., Akin C., and Gilfillan A.M. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br. J. Pharmacol. 154 (2008) 1572-1582
22. Lachowicz J.L., Post G.S., and Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J. Vet. Intern. Med. 19 (2005) 860-864
23. Liska W., MacEwan E., Zaki F., and Garvey M. Feline systemic mastocytosis: a review and results of splenectomy in seven cases. J. Am. Anim. Hosp. Assoc. 15 (1979) 589-597
24. Litster A.L., and Sorenmo K.U. Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J. Feline Med. Surg. 8 (2006) 177-183
25. London C.A., Galli S.J., Yuuki T., Hu Z.Q., Helfand S.C., and Geissler E.N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27 (1999) 689-697
26. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T., Jacobs P., Tang L.H., and Modlin I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12 (1996) 312-314
27. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., McMahon G., and Longley B.J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 (2002) 1741-1744
28. Metcalfe D.D. Mast cells and mastocytosis. Blood 112 (2008) 946-956
29. Molander-McCrary H., Henry C., Potter K., Tyler J., and Buss M. Cutaneous mast cell tumours in cats: 32 cases (1991-1994). J. Am. Anim. Hosp. Assoc. 34 (1998) 281-284
30. Morini M., Bettini G., Preziosi R., and Mandrioli L. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. J. Histochem. Cytochem. 52 (2004) 705-708
31. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., and Metcalfe D.D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10560-10564
32. Rebuzzi L., Willmann M., Sonneck K., Gleixner K.V., Florian S., Kondo R., Mayerhofer M., Vales A., Gruze A., Pickl W.F., Thalhammer J.G., and Valent P. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet. Immunol. Immunopathol. 115 (2007) 320-333
33. Rix U., Hantschel O., Dürnberger G., Remsing-Rix L.L., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Köcher T., and Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110 (2007) 4055-4063
34. Riva F., Brizzola S., Stefanello D., Crema S., and Turin L. A study of mutations in the c-kit gene of 32 dogs with mastocytoma. J. Vet. Diagn. Invest. 17 (2005) 385-388
35. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., and Akin C. Dasatinib (BMS-354825) inhibits KITD816 V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108 (2006) 286-291
36. Valent P. The riddle of the mast cell: kit(CD117)-ligand as the missing link?. Immunol. Today 15 (1994) 111-114
37. Valent P., Akin C., Sperr W.R., Mayerhofer M., Födinger M., Fritsche-Polanz R., Sotlar K., Escribano L., Arock M., Horny H.P., and Metcalfe D.D. Mastocytosis: pathology, genetics, and current options for therapy. Leuk. Lymphoma. 46 (2005) 35-48
38. Valent P., Ashman L.K., Hinterberger W., Eckersberger F., Majdic O., Lechner K., and Bettelheim P. Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73 (1989) 1778-1785
39. Valent P., Ghannadan M., Akin C., Krauth M.T., Selzer E., Mayerhofer M., Sperr W.R., Arock M., Samorapoompichit P., Horny H.P., and Metcalfe D.D. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur. J. Clin. Invest. 34 S2 (2004) 41-52
40. Valent P. Systemic mastocytosis. Cancer Treat. Res. 142 (2008) 399-419
41. Van Cruchten S., and Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 31 (2002) 214-223
42. Verstovsek S., Tefferi A., Cortes J., O'Brien S., Garcia-Manero G., Pardanani A., Akin C., Faderl S., Manshouri T., Thomas D., and Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res. 14 (2008) 3906-3915
43. Zemke D., Yamini B., and Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet. Pathol. 39 (2002) 529-535